Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11104715
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
granted -
US 11104901
Brush polymer-assisted compaction of oligonucleotides
granted -
US 11104729
Anti-IL-33 antibodies and uses thereof
granted -
US 11104730
Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
granted -
US 11102961
Non-human animals having a humanized lymphocyte-activation gene 3
granted -
US 11103436
Peptide exhibiting wrinkle-improving activity and uses thereof
granted -
US 11103460
Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
granted -
US 11104737
ACVR2A-specific antibody and method of treatment of muscle atrophy
granted -
US 11104918
Universal donor cells
granted -
US 11103461
Process for encapsulating soluble biologics, therapeutics, and imaging agents
granted -
US 11103479
Small organic molecules for use in the treatment of neuroinflammatory disorders
granted -
US 11103491
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted -
US 11103454
Wax foamable vehicle and pharmaceutical compositions thereof
granted -
US 11103504
Combination of a DNA condensation-inducing compound and an Eis inhibitor for antibiotic treatment
granted -
US 11103520
Analogs of N-acetlyglucosamine and uses thereof
granted -
US 11103523
Self-assembled brush block copolymer-nanoparticles for drug delivery
granted -
US 11103528
Slow release calcium composition
granted -
US 11103514
Treatment of muscular dystrophy
granted -
US 11103532
Chimeric protein
granted -
US 11103572
Thermal inactivation of rotavirus
granted -
US 11103581
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11103591
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 11103622
Thromboresistant/bactericidal s-nitroso-n-acetylpenicillamine (SNAP)-doped nitric oxide release polymers with enhanced stability
granted -
US 11103601
Lymph targeting nuclear magnetic contrast agent using brown algae polysaccharide as carrier and preparation method and use thereof
granted -
US 11104660
PDE4D inhibitors
granted -
US 11104704
Peptide having cytoprotective effect against environmental pollutant and use thereof
granted -
US 11104719
Recombinant clusterin and use thereof in the treatment and prevention of disease
granted -
US 11104689
Influenza virus replication inhibitor and use thereof
granted -
US 11104684
Dimers of covalent NFKB inhibitors
granted -
US 11103541
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
granted -
IT 202000004582
COMPOSIZIONE FARMACEUTICA UTILE PER IL TRATTAMENTO E LA PREVENZIONE DELL’ATROFIA E DELLA SECCHEZZA VAGINALE.
granted -
US 11111310
Chimeric polypeptides and methods of altering the membrane localization of the same
granted -
US 11111238
Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
granted -
US 11110178
Antibody adjuvant conjugates
granted -
US 11110177
ASH1L degraders and methods of treatment therewith
granted -
US 11110108
Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
granted -
US 11110095
Pyrimidine compounds as JAK kinase inhibitors
granted -
US 11110092
Methods of treating hematologic cancers
granted -
US 11110089
Pyridazinones and their use in the treatment of cancer
granted -
US 11110086
Compounds useful as inhibitors of ATR kinase and combination therapies thereof
granted -
US 11110080
Small molecule inhibitors of bacterial efflux pumps and methods of using same
granted -
US 11110129
Method for treating multiple sclerosis
granted -
US 11110103
Inhibitors of glucocorticoid receptor
granted -
US 11110090
Aminopyrimidines as ALK inhibitors
granted -
US 11110099
Natural combination hormone replacement formulations and therapies
granted -
US 11110093
Sustained release small molecule drug formulation
granted -
US 11110082
Tyrosine kinase inhibitors
granted -
US 11110067
Inhibition of mammalian target of rapamycin
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.